Anti-HA Antibody Market - Top Companies and Manufacturers

In the News

• Pfizer Inc. and BioNTech SE released positive topline outcomes from a Phase 1/2 study (NCT05596734) analyzing the protection, acceptability, and immunogenicity of mRNA-dependent mixture vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. The information from the investigation demonstrated that the organizations' lead preparation showed powerful immune replies to influenza A, influenza B, and SARS-CoV-2 strains.
• Pfizer Inc. presented information across its contagious disease portfolio at IDWeek 2023 occurred in Boston from October 11-15, 2023. Information from 45 abstracts shows the developments Pfizer is making in helping stop and cure specific contagious diseases, specifically respiratory illnesses. This comprised research highlighted in the IDWeek press program analyzing the possible public health influence of ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the organization’s double respiratory syncytial virus prefusion F (RSVpreF) vaccine for motherly immunization to safeguard infants against RSV illness.